DDInter484 DDInter704
Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the breakpoint cluster region (BCR) gene transcribe the chimeric protein BCR-ABL. BCR-ABL is associated with the uncontrolled activity of the ABL tyrosine kinase and is involved in the pathogenesis of CML and 15-30% of ALL cases.[A11377,A33432] Dasatinib also inhibits a spectrum of kinases involved in cancer, including several SRC-family kinases. Unlike [imatinib], another tyrosine kinase used for the treatment of CML and Ph-positive ALL, dasatinib inhibits the active and inactive conformations of the ABL
Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.
Dasatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Everolimus
Dasatinib {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Everolimus
Dasatinib {u} (Compound) downregulates {v} (Gene) CDK5R1
CDK5R1 {u} (Gene) is upregulated by {v} (Compound) Everolimus
Dasatinib {u} (Compound) upregulates {v} (Gene) MCOLN1
MCOLN1 {u} (Gene) is upregulated by {v} (Compound) Everolimus
Dasatinib {u} (Compound) binds {v} (Gene) LYN
LYN {u} (Gene) is upregulated by {v} (Compound) Everolimus
Dasatinib {u} (Compound) binds {v} (Gene) and {u} (Compound) upregulates {v} (Gene) KIT
KIT {u} (Gene) is upregulated by {v} (Compound) Everolimus
Dasatinib {u} (Compound) downregulates {v} (Gene) RPIA
RPIA {u} (Gene) is downregulated by {v} (Compound) Everolimus
Dasatinib {u} (Compound) upregulates {v} (Gene) ECH1
ECH1 {u} (Gene) is downregulated by {v} (Compound) Everolimus
Dasatinib {u} (Compound) binds {v} (Gene) CSK
CSK {u} (Gene) is downregulated by {v} (Compound) Everolimus
Dasatinib {u} (Compound) causes {v} (Side Effect) Pericardial effusion
Pericardial effusion {u} (Side Effect) is caused by {v} (Compound) Everolimus
Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Everolimus (Compound)
Dasatinib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Everolimus (Compound)
Dasatinib (Compound) downregulates CDK5R1 (Gene) and CDK5R1 (Gene) is upregulated by Everolimus (Compound)
Dasatinib (Compound) upregulates MCOLN1 (Gene) and MCOLN1 (Gene) is upregulated by Everolimus (Compound)
Dasatinib (Compound) binds LYN (Gene) and LYN (Gene) is upregulated by Everolimus (Compound)
Dasatinib (Compound) binds KIT (Gene) and Dasatinib (Compound) upregulates KIT (Gene) and KIT (Gene) is upregulated by Everolimus (Compound)
Dasatinib (Compound) downregulates RPIA (Gene) and RPIA (Gene) is downregulated by Everolimus (Compound)
Dasatinib (Compound) upregulates ECH1 (Gene) and ECH1 (Gene) is downregulated by Everolimus (Compound)
Dasatinib (Compound) binds CSK (Gene) and CSK (Gene) is downregulated by Everolimus (Compound)
Dasatinib (Compound) causes Pericardial effusion (Side Effect) and Pericardial effusion (Side Effect) is caused by Everolimus (Compound)